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Abstract 
Integrins have become key targets for molecular imaging and for selective delivery of an-
ti-cancer agents. Here we review recent work concerning the targeted delivery of antisense 
and siRNA oligonucleotides via integrins. A variety of approaches have been used to link 
oligonucleotides to ligands capable of binding integrins with high specificity and affinity. This 
includes direct chemical conjugation, incorporating oligonucleotides into lipoplexes, and use 
of various polymeric nanocarriers including dendrimers. The ligand-oligonucleotide conjugate 
or complex associates selectively with the integrin, followed by internalization into endo-
somes and trafficking through subcellular compartments. Escape of antisense or siRNA from 
the endosome to the cytosol and nucleus may come about through endogenous trafficking 
mechanisms, or because of membrane disrupting capabilities built into the conjugate or 
complex. Thus a variety of useful strategies are available for using integrins to enhance the 
pharmacological efficacy of therapeutic oligonucleotides. 
Key words: Gene therapy; Integrin; RGD peptides; Antisense and siRNA oligonucleotides; Endo-
some escape. 
The value of integrins for the delivery of an-
tisense and siRNA oligonucleotides  
Therapy  with  oligonucleotides:  the  delivery  issue. 
Antisense and siRNA oligonucleotides have tremen-
dous  potential  as  therapeutic  agents  in  cancer  and 
other diseases. However, despite recent advances in 
oligonucleotide  chemistry  and  pharmacology  [1-3], 
the effective delivery of these molecules to their in-
tracellular sites of action within tissues remains a key 
impediment  to  progress  [4].  Antisense  oligonucleo-
tides  usually  act  via  selective  degradation  of  com-
plementary pre-mRNA through recruitment the nu-
clear enzyme RNase H, while siRNA loads on to the 
cytoplasmic RISC complex to monitor and ultimately 
degrade fully complementary mRNA; thus both an-
tisense  and  siRNA  provide  powerful  means  for 
down-regulation of gene expression [5-6]. Addition-
ally, antisense molecules can be used to shift patterns 
of pre-mRNA splicing [7], or to regulate gene expres-
sion via antagonizing miRNA [8]. All of this can be 
done effectively in cell culture via potent transfection 
agents such as cationic lipids or polymers. However, 
because of toxicity issues, these approaches are some-
times not readily adapted to the in vivo situation. Thus 
much of the animal experimentation and clinical in-
vestigation  to  date  using  antisense  or  siRNA  have 
been  done  with  oligonucleotides  administered  in 
‘free’  form,  without  any  transfection  reagent  [6,  9]. 
However,  although  there  has  been  much  progress, 
many researchers in the oligonucleotide therapeutics 
field believe that the efficacy of antisense or siRNA 
could be substantially enhanced by use of appropriate 
delivery systems [10-11]. Recent investigations from 
our  laboratory  [12-13]  and  others  [11,  14]  have 
stressed  the  value  of  using  various  forms  of  recep-
tor-mediated endocytosis as an cell entry pathway for 
oligonucleotides. Via this general approach, substan-
tial increases in cellular uptake, intracellular delivery, 
and pharmacological effects have been attained. Theranostics 2011, 1 
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Integrins  as  targets  for  oligonucleotide  delivery. 
Members of the integrin family of cell surface adhe-
sion receptors seem particularly attractive target for 
enhancing the efficiency and selectivity of delivery of 
antisense and siRNA oligonucleotides. The integrins 
are  a  family  of  heterodimeric  cell  surface  receptors 
that have important roles during development and in 
the adult organism [15]. One of the major function of 
integrins  is  to  provide  mechanical  transmembrane 
linkages between extracellular matrix proteins such as 
fibronectin, collagen and laminin and the actin cyto-
skeleton [16]. Integrins also play an important role in 
regulating  several  signal  transduction  pathways 
[17-19]. In particular, our laboratory has explored the 
connection between integrins and the Erk MAP kinase 
mitogenic pathway [20-22]. A number of integrins are 
differentially expressed between tumors and normal 
tissue [23-24], with the integrin αvβ3 being of partic-
ular interest in this context since it is highly expressed 
in angiogenic endothelia and in some types of tumor 
cells [25-26]. It is known that integrins are recycled via 
endocytotic processes [27-31]; thus the αvβ3 integrin 
is thought to be primarily internalized via caveolae 
and/or  lipid  raft-rich  vesicles  [32-33]. A  number  of 
integrins, including αvβ3, then traffic through the Rab 
11 positive perinuclear recycling compartment prior 
to returning to the cell surface [29, 34-35]. Thus integ-
rins  are  relatively  abundantly  expressed  (typically 
~105  copies  per  cell),  are  efficiently  internalized  by 
endocytosis,  and  some  members  of  this  family  are 
differentially expressed on tumor cells; in aggregate 
these  characteristics  suggest  that  targeting  integrins 
could be an excellent approach for delivery of thera-
peutic oligonucleotides. 
Direct conjugates between oligonucleotides 
and integrin targeting ligands 
Direct conjugation of functional agents such as 
cell  penetrating  peptides  (CPPs)  to  oligonucleotides 
allows  enhanced  cellular  uptake  [36];  thus  direct 
conjugation strategies have an important position in 
drug  delivery  approaches.  Because  many  integrin 
ligands, including RGD, are peptides, the conjugation 
techniques for CPPs should be applicable to conjuga-
tion of integrin ligands. A typical approach [37] for 
conjugation  is  formation  of  stable  chemical  bonds 
with reactive groups in both molecules, such as thi-
oether,  disulfide,  amide,  oxime  and  hydrazone.  Re-
cently,  a  technique  with  click  chemistry  [38-39]  has 
been also developed. Up to now, there are only a few 
reports  of  direct  conjugation  of  integrin  ligands  to 
oligonucleotides.  Defrancq  and  colleagues  [40-45] 
have reported on various conjugates with linkages of 
thiazolidine and oxime. An oligonucleotide with an 
aldehyde moiety was coupled to RGD bearing a cys-
teine residue for thiazolidine formation, and an ami-
nooxy group for oxime formation (and vice versa) (Fig 
1, a). These effectively reacted without a protection 
strategy and under mild aqueous conditions. We also 
reported a direct conjugation of a bivalent-RGD that 
had a strong binding affinity to integrin receptors [13]. 
The  bivalent-RGD  conjugated  oligonucleotide  was 
successfully synthesized by formation of a thioether 
linkage with a maleimide group in the bivalent-RGD 
and a thiol group introduced into the 5’-terminal of 
the  oligonucleotide  (Fig  1,  b).  Thus,  this  strategy, 
which directly conjugates integrin ligand to oligonu-
cleotide, has a great advantage from the viewpoint of 
simplified synthesis. 
 
Figure 1. Synthesis of RGD-conjugated oligonucleotides. Theranostics 2011, 1 
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In our hands integrin-RGD conjugates have been 
a valuable tool for oligonucleotide delivery. Thus we 
used a bivalent form of RGD to target an antisense 
oligonucleotide  to  αvβ3–expressing  human  melano-
ma  cells  [13]  (Fig  2).  This  oligonucleotide  was  de-
signed to correct splicing of a luciferase reporter cas-
sette  that  contained  an  aberrant  intron,  thus 
up-regulating luciferase expression and providing a 
positive  read-out  for  oligonucleotide  delivery.  The 
RGD-oligonucleotide  produced  a  several-fold  en-
hancement of effect as compared to unmodified anti-
sense. The mechanism of uptake seemed to track the 
caveolar uptake pathway known for the αvβ3 integ-
rin,  while  eventually  some  oligonucleotide  was  de-
livered to the trans-Golgi. Recent work has suggested 
that  the  RGD—oligonucleotide  and  the  unmodified 
oligonucleotide  enter  cells  by  completely  different 
endocytotic pathways [46].  
 
 
 
Figure  2.  Molecular  model  of  a  bivalent-RGD  peptide 
conjugated to an antisense oligonucleotide. 
 
Integrin targeted lipoplexes 
Cationic lipids have a long history as gene de-
livery  carriers  [47].  Lipofectamine,  DOTAP,  Gene-
porter, DOTMA, to name a few, have already been 
commercialized and widely used [48-49]. They form 
complexes with nucleic acids, also called lipoplexes, 
mainly  through  charge-charge  interaction  and  hy-
drophobic forces [50]. At physiological pH, the inter-
nal structure of the lipoplexes are laminar, onion-like, 
with  nucleic  acid  layers  sandwiched  between  lipid 
bilayers as determined by small angle x-ray scattering 
and  transimission  electric  microscopy  [51-53].  The 
lipoplexes usually have a positive surface potential. 
Thus  the  unmodified  lipoplexes  enter  the  cells 
through  endocytosis,  as  observed  by  electron  mi-
croscopy  [54].  However,  this  process  is  nonspecific. 
To preferentially deliver the lipoplexes into cells spe-
cifically expressing αvβ3 integrin, targeted lipoplexes 
were prepared through incorporating RGD peptide. 
The formed targeted lipoplexes improved the delivery 
of functional genes or siRNA into various cell types 
including HUVEC, HeLa, 293T, NIH3T3, A549, U87, 
MDA-MB-231, human airway epithelial cells, human 
tracheal cells, and activated platelets [55-64]. 
Incorporation  of  polyethylene  glycol  (PEG) 
shielding is essential to introduce stealth-like proper-
ties [65-66]. Lipoplexes modified this way become less 
susceptible  to  uptake  by  phagocytes  and  it  also  re-
duces  the  nonspecific  interaction  toward  negatively 
charged  sulfated  proteoglycans  on  the  cell  surface, 
thus  allowing  long  circulation  time  [67-68].  Adding 
targeting  moieties  to  stealth-like  lipoplexes  is  ex-
pected  to  achieve  high  delivery  specificity.  PEG  is 
widely used to provide shielding for delivery systems 
because of its biocompability, neutrality, hydrophilic-
ity,  flexibility,  variable  length  and  bulky  hydrody-
namic  volume  [69-70].  Martin-Herranz  et  al.  exten-
sively explored the influence of PEG chain length on 
lipoplex properties  [71]. X-ray scattering found that 
incorporation  of  PEG  with  molecular  weights  400 
(PEG400) or 2000 (PEG2000) did not change the in-
ternal  laminar  phase  of  DOTAP-DNA  complex. 
However,  only  PEG2000  provided  sufficient  shield-
ing, which was evidenced by reduced inter-lipoplex 
interaction  leading  to  blocked  aggregation,  and  by 
interrupted cell-lipoplex interaction showing reduced 
transfection  efficiency  in  fibroblasts.  These  authors 
further  discovered  that  the  shielding  effect  of  PEG 
was  less  dependent  on  PEG  density.  For  example, 
PEG400 even up to 20% ratio to cationic lipid didn’t 
introduce  effective  shielding.  However,  PEG2000 
completely  shielded  lipoplexes  at  a  6%  ratio.  Thus 
PEG with molecular weight above 2000 is widely used 
in developing long-circulating lipoplexes [63, 72]. Be-
sides providing a protective coat, it also acts as tether 
for targeting ligands to develop targeted lipoplex de-
livery systems [57-58, 64].  
Recently, Wang et al. developed an integrin tar-
geted lipoplex and tested its siRNA delivery efficien-
cy in a mouse tumor model [64]. This targeted lipo-
plex utilized a novel multifunctional lipid carrier ab-
breviated  as  EHCO  to  form  complexes  with  an-
ti-HIF-1a  siRNA;  the  intent  was  to  knock  down 
HIF-1a, which is a key transcription factor responsible 
for tumor survival in hypoxic environments. RGD in 
the  form  of  cyclo(RGDfK)  was  conjugated  to  PEG 
 Theranostics 2011, 1 
 
http://www.thno.org 
214 
with molecular weight 3400 and directly linked onto 
the surface of this lipoplex through reaction between a 
maleimide group (-Mal) group on PEG and free thiol 
(-SH) groups on the EHCO. The molar ratio between 
targeting ligand and lipid carrier was 2.5%. For in vitro 
delivery  in  U87  cells,  flow  cytometry,  confocal  mi-
croscopy, and luciferase assays consistently demon-
strated that PEG effectively reduced the nonspecific 
cell  entry  of  the  lipoplex,  while  RGD  increased  the 
receptor  mediated  delivery  and  the  activity  of  the 
loaded siRNA. This RGD-directed lipoplex was then 
systemicaly delivered into athymic mice bearing hu-
man glioma U87 xenografts via intravenous injection 
using anti-HIF-1a siRNA dosed 2.5 mg/kg. At day 14, 
after five doses of siRNA, the tumor volume of the 
mice  receiving  targeted  lipoplex  was  much  smaller 
than  the  mice  receiving  nonmodified  lipoplex  with 
significance  (P  <  0.05).  This  result  validated 
RGD-directed  stealth-like  lipoplexes  as  an  effective 
systemic  nucleic  acid  delivery  system.  It  should  be 
pointed  out  that  delivery  targeting  integrins  could 
achieve dual effects, with delivery of nucleic acids to 
both  αvβ3  integrin-expressing  angiogenic  epithelial 
cells and αvβ3 positive tumor cells [64, 73].  
Integrin targeted polymeric carriers 
RGD-surface-modified  nanoparticles,  including 
polyplexes and liposomes, have been utilized to de-
liver therapeutic genes for a decade  [74]. However, 
adenovirus, with a diameter of 60-90 nm and using 
integrin  as  a  secondary  receptor  for  internalization 
[75], can be considered as the first integrin targeted 
nanoparticle. Seeking to emulate the superior trans-
fection  efficiency  of  adenovirus,  polyethylenimine 
(PEI) was conjugated directly to the integrin-binding 
peptide  CYGGRGDTP,  which  was  then  condensed 
with  plasmid DNA to form particles 30-100 nm di-
ameter  [76].  PEI-RGD/DNA  complexes  showed  su-
perior  in  vitro  transfection  efficiency  compared  to 
those with RGE in the peptide sequence [76], repre-
senting an initial success in mimicking adenovirus for 
gene delivery. 
Further  work  sought  to  overcome  the  intrinsic 
problems  of  PEI  polyplexes,  such  as  non-specific 
binding to cell surfaces and serum proteins. Polyeth-
ylene glycol (PEG) was used as a spacer between RGD 
and PEI, and then the RGD-PEG-PEI polymers were 
condensed with plasmid DNA [77-78] or siRNA [79]. 
The presence of PEG groups forms a hydrated barrier 
surrounding the nanoparticles that shields the defects 
in  the  cationic  polyplexes  and  inhibits  non-specific 
adsorption. Besides improvement of the in vitro activ-
ity, the latter study showed that RGD-PEG-PEI parti-
cles  accumulated  in  tumor  tissues  overexpressing 
integrins and selectively delivered VEGFR2 siRNA to 
suppress  tumor  growth  and  angiogenesis  [79].  Re-
cently,  RGD-contained  polymers  have  been  further 
optimized. Polycation/DNA complexes were coated 
with  multivalent  N-(2-hydroxypropyl)methacry-
lamide (HPMA) copolymers in one study [80]. In an-
other  study,  RGD-PEG-block-poly(lysine)  was  syn-
thesized  for  gene  delivery  [81].  Interestingly,  con-
densing with this polymer did not enhance the cellu-
lar uptake of plasmid DNA, but improved expression 
of the plasmid dramatically in HeLa cells displaying 
αvβ3 integrin [81]. Initial studies suggested that the 
presence  of  RGD  peptide  changed  the  intracellular 
trafficking  route  of  the  PEI  polyplexes  to  a  caveo-
lar-mediated pathway followed by trafficking to the 
perinuclear region, thereby avoiding lysosomal deg-
radation of delivered genes  [81]. Although the pro-
posed mechanism was intriguing, the methods in this 
study, which heavily relied on microscopic observa-
tion, were descriptive and non-quantitative. Utilizing 
pharmacological and molecular inhibitors of endocy-
totic pathways can provide mechanistic information 
of intracellular trafficking of nanoparticles [4]. 
Other than PEI, RGD has also been conjugated to 
other polymeric carriers for delivery of nucleic acids, 
for example, carbon nanotubes [82], dendrimers [83], 
albumin [12], and gold nanoparticles [39]. Inspired by 
the  clustered  RGD  ligands  displayed  on  five  pen-
ton-base  proteins  in  adenovirus,  multiple  RGD  lig-
ands were conjugated to gold nanoparticles to form so 
called RGD nanoclusters, and then were condensed 
with DNA/PEI complexes [39]; the polyplex demon-
strated superior in vitro activity. Another interesting 
RGD-based particle involved albumin conjugates (Fig 
3), in which splice-shifting antisense oligonucleotides 
and PEG-RGD are linked to the same albumin mole-
cules [12]. The resultant complex (diameter of 6 nm) 
was smaller than most nanoparticles, and may obtain 
a better balance of avoiding being scavenged in the 
liver versus retention in tumor sites [12].  
Compared to direct conjugates between nucleic 
acids  and  RGD  ligands,  polymeric  carriers  have  a 
higher  cargo  capacity,  which  may  lead  to  a  better 
pharmacodynamics.  The  binding  affinities  of  RGD 
peptides to integrin are typically at nanomolar levels, 
for example, 16 nM for the binding of a bivalent RGD 
peptide to the αvβ3 integrin [84]. For delivery of the 
same amount of therapeutic nucleic acids, direct con-
jugates have more RGD ligands thus possibly satu-
rating  integrin  receptors  and  resulting  in  inefficient 
receptor-mediated  endocytosis.  Another  important 
factor affecting pharmacodynamics of nucleic acids is 
intracellular trafficking, from cellular uptake, vesicle 
trafficking, to release of the cargo at the target sites. Theranostics 2011, 1 
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Initial studies have indicated its importance [13, 81], 
however,  more  pharmacological  and  cell  biological 
studies are needed to elucidate the molecular mecha-
nisms of nucleic acid trafficking. 
 
 
Figure 3. Synthesis of an RGD targeted carrier for oligonucleotides using human serum albumin. 
 
Integrin targeted dendrimers 
Dendrimers are spherical macromolecules with 
numerous  inner  branches,  and  are  attractive  mole-
cules for the delivery of various types of nucleic acids 
(e.g., antisense oligonucleotide, siRNA, and plasmids) 
as well as traditional small organic molecules [85-91]. 
As a delivery modality for nucleic acid, dendrimers 
have many advantages in terms of molecular struc-
ture, size and surface functional groups [92]. Particu-
larly,  by  selecting  the  generation  of  dendrimer,  the 
size of dendrimer/nucleic acid complexes is adjusta-
ble to less than 200 nm, which is an important factor 
for tissue distribution through capillaries (~5 um) and 
passage  through  fenestrae  between  discontinuous 
endotherial cells (30-500 nm) of liver, spleen and bone 
marrow  [93].  Cellular  delivery  of  nucleic  acids  by 
dendrimers  has  been  limited  in  its  effectiveness  as 
well as in vivo efficacy. Excessive positive charge on 
dendrimer  surfaces  causes  cytotoxicity  due  to 
non-specific  interactions  with  negatively  charged 
proteins on cell membranes [94-95] Also interactions 
with various serum proteins during blood circulation 
can disrupt delivery function, damaging nucleic acid 
before  it  gets  to  the  target  by  the  action  of  the  en-
do/exo nucleases in blood [96]. 
The mechanism for dendrimer internalization in 
cells  has  been  generally  considered  to  be  receptor 
mediated  endocytosis  which  follows  an  endo-
some/lysosome  pathway.  However,  recent  studies 
indicate that cellular internalization of dendrimers is 
diverse and cell type dependent with different inter-
nalization  pathways  in  different  cells  [97].  Clath-
rin-coated  pits,  macropinocytosis,  the  caveo-
lae-dependent  pathway,  and  clathrin-  and  caveo-
lin-independent pathways were reported for the cel-
lular uptake and transport of dendrimer/nucleic acid 
complexes  [97-100].  For  endosomal  release  of  den-
drimer and nucleic acid into cytoplasm, protonation 
in the acidic pH and Cl- ion influx in the late endo-
somal  stage  induces  rapid  swelling  of  the  polymer 
matrix as well as conformational change, following by 
endosomal  rupture  thereby  releasing  nucleic  acids 
into the cytoplasm [93]. A recent study by Lee and 
Larson revealed a pore formation mechanism by the 
positively  charged  dendrimer  [101].  Dendrimers 
caused the formation of holes on the cell membrane 
leading to nonselective internalization into cell.  The 
endocytotic pathway of RGD-dendrimer conjugates is 
little  known  and  needs  further  investigation.  Our 
previous studies with RGD carriers indicates that ini-
tial uptake of nucleic acid complexes by integrin re-
ceptors was followed via smooth vesicle trafficking, 
not clathin-coated pits, and at later points the com-
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plexes  entered  into  endomembrane  compartments 
[11-12]. 
The surface amino groups of dendrimers can be 
modified by attaching molecular ligands for selective 
targeting, for example, to recognize certain receptors 
expressed  in  disease  sites  [102-106].  The  αvβ3  and 
αvβ5 integrins have been of particular interest since 
they are highly expressed on the luminal surface of 
endothelial cells during angiogenesis and also certain 
types of malignant cells [19, 107]. High-affinity cyclic 
RGD  peptide,  (c(RGDfK))  selectively  recognizing 
αvβ3 and αvβ5 integrin receptors was chosen to attain 
high affinity binding to this receptor [108]. PAMAM 
dendrimer-RGD  conjugates  complexed  with  siRNA 
enhanced the siRNA delivery and reduced the pro-
gression of angiogenesis in the treatment of solid tu-
mors [83, 109].  
Pegylating  the  dendrimer  surface  shields  posi-
tive charge of the dendrimer thus reducing nonspe-
cific interactions with cell membranes and attenuates 
oxidative stress on the cell [110-111]. Also pegylation 
increases  the  circulation  time  of  the  dendrimer  in 
blood by avoiding the interaction of dendrimer sur-
face  amino  groups  with  serum  proteins  [112-113]. 
Prolonged  circulation  time  in  blood  enhances  the 
drug accumulation in diseased tissues (tumor or in-
flammatory site) via the EPR (enhanced permeability 
and  retention)  effect  [114-115].  Den-
drimer-RGD-pegylation  is  a  well-designed  delivery 
adjunct that improves target selectivity as well as sta-
bility  of  the  dendrimer  complex  with  nucleic  acids. 
Efficient intramuscular gene expression was mediated 
by PEG-conjugated PAMAM dendrimer [116-117].  
The intracellular codelivery of nucleic acids and 
traditional chemotherapeutic drugs using dendrimers 
can be a promising approach for the development of 
multifunctional-drug carriers. With targeting ligands 
attached, the nanospace of the dendrimer interior can 
be used as a vehicle for encapsulation of chemother-
apeutic agents (e.g., doxorubicin or paclitaxel) while 
the  outer  shell  just  beneath  the  dendrimer  surface 
serves  for  nucleic  acid  shielding  from  the  action  of 
endo/exo nucleases [112]. In recent study a genera-
tion-3 (G3) dendrimer was conjugated with PEG and 
RGD for codelivery of doxorubicin (DOX) and siRNA. 
Doxorubicin (DOX) was coupled to the RGD targeted 
nanoglobule via a degradable disulfide spacer to give 
G3-[PEG-RGD]-[DOX];  G3-[PEG-RGD]-[DOX]  was 
further  complexed  with  siRNA  [109].  The  siRNA 
complexes of the targeted conjugate resulted in sig-
nificantly higher gene silencing efficiency in U87-Luc 
cells than those of control conjugates G3-[PEG-RGD] 
and G3-[DOX]. Kang et. al. evaluated the efficiency of 
folate-polyamidoamine  dendrimer  conjugates 
(FA-PAMAM) for the in situ delivery of therapeutic 
antisense  oligonucleotides  (ASODN)  to  inhibit  the 
growth  of  C6  glioma  cells.  ASODN  from  the 
FA-PAMAM knocked down EGFR expression in C6 
glioma cells, both in vitro and in vivo [102]. Quintana 
and colleagues synthesized an ethylenediamine core 
PAMAM  dendrimer  generation  5  which  was  cova-
lently conjugated to folic acid, fluorescein, and meth-
otrexate [118]. This complex provides targeting, im-
aging and intracellular drug delivery capability with 
100-fold decreased cytotoxicity over free methotrex-
ate.  Other  multifunctional  dendrimers  have  been 
prepared by covalently linking tumor targeting mol-
ecules  such  as  folic  acid  (FA)  or  HER2-antibody,  a 
sensing fluorescent molecule, and a chemotherapeutic 
drug  such  as  methotrexate  or  taxol  [103,  119-120]. 
While these latter examples do not involve integrins, 
they establish approaches that could also be used in 
the integrin targeting area. 
Conclusions 
The integrin family of receptors provides inter-
esting and useful targets for delivery of therapeutic 
oligonucleotides. Much has already been done using 
simple RGD peptides associated with a variety of car-
rier  types  (lipoplexes,  dendrimers,  other  polymers). 
Additional  peptide  or  small  molecule  ligands  for 
non-RGD  binding  integrins  are  becoming  available 
and should open the way to target additional mem-
bers of this large receptor family. Finally, while many 
reports have appeared, we still know relatively little 
about the mechanisms involved in integrin-mediated 
delivery  of  nucleic  acids;  this  will  be  an  important 
theme for future investigation.  
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